Mobile Health Application As A Real-World Data Resource: Self-Recorded Weight Reduction With Once-Weekly Semaglutide

A mobile health application (mHealth app) with treatment planning, body weight and dose tracking features has been developed to support patients with type 2 diabetes (T2D) initiating once-weekly (OW) semaglutide, a glucagon-like peptide-1 analog. Here, we assess app users’ self-recorded weight loss (WL) data.Of 2,820 active users (≤3 consecutive weeks without interacting with [opening] the app over the 12-week initiation period), 1,506 had at least four recorded weight entries and were included in the analysis. Baseline weight was defined as the first weight reported between weeks 1 and 2 after initiating treatment; subsequent reported weights were averaged over 2-week intervals. Mean weight over time (up to 18 weeks) was estimated using a mixed model for repeated measurement. Of 1,506 users, 1,090 had baseline measurements (mean 102.0 kg), and 907 had week 17-18 measurements (mean 97.3 kg).The mean self-reported WL was 4.55% (4.65 kg; p<0.0001) from baseline to week 18 (Figure). A sensitivity analysis for users reporting a baseline weight (n=1,090), showed similar mean WL (4.53% [4.60 kg]). The results are in line with those from real-world evidence (RWE) studies like SPARE (retrospective) and SURE (prospective).These findings suggest that mHealth app data can complement OW semaglutide RWE programs in T2D treatment.View largeDownload slideView largeDownload slide DisclosureU. Bodholdt: None. S. Birot: Employee; Self; Novo Nordisk A/S. A. Catarig: Employee; Self; Novo Nordisk. U. Erhan: Employee; Self; Novo Nordisk A/S. F. K. Knop: Advisory Panel; Self; MSD Corporation, Novo Nordisk A/S, Sanofi, Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, Pharmacosmos, Zealand Pharma A/S, Research Support; Self; Novo Nordisk A/S, Zealand Pharma A/S, Speaker’s Bureau; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, MSD Corporation, Novo Nordisk A/S.FundingNovo Nordisk A/S